| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BMS-509744 | GDSC1000 | pan-cancer | AAC | 0.06 | 0.3 |
| mRNA | KU 0060648 | CTRPv2 | pan-cancer | AAC | 0.039 | 0.3 |
| mRNA | Doxorubicin | GDSC1000 | pan-cancer | AAC | 0.04 | 0.3 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.037 | 0.3 |
| mRNA | DMOG | GDSC1000 | pan-cancer | AAC | -0.037 | 0.3 |
| mRNA | WZ3105 | GDSC1000 | pan-cancer | AAC | 0.033 | 0.3 |
| mRNA | BRD-K94991378 | CTRPv2 | pan-cancer | AAC | 0.042 | 0.3 |
| mRNA | canertinib | CTRPv2 | pan-cancer | AAC | 0.039 | 0.3 |
| mRNA | SB-743921 | CTRPv2 | pan-cancer | AAC | 0.035 | 0.3 |
| mRNA | AZD1480 | CTRPv2 | pan-cancer | AAC | 0.058 | 0.3 |